Tourmaline Bio, Inc.
TRML · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $1 | $1 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $1 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | -100% | – | – |
| Gross Profit | $0 | -$0 | $0 | -$0 |
| % Margin | – | – | 50% | – |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | -55,565% | – |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | -55,587.5% | – |
| EPS Diluted | -0.9 | -0.89 | -0.86 | -0.78 |
| % Growth | -1.1% | -3.5% | -10.3% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | $0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |